

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2018

MRI INTERVENTIONS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

5 Musick
Irvine, Ca. 92618
(Address of principal executive offices, zip code)

(949) 900-6833
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On February 6, 2018, MRI Interventions, Inc. (the “Company”) issued a press release announcing its financial performance for the fourth fiscal quarter and fiscal year ended December 31, 2017. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

[Exhibit 99.1 Press Release dated February 6, 2018.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 6, 2018

MRI INTERVENTIONS, INC.

By: /s/ Harold A. Hurwitz

Harold A. Hurwitz
Chief Financial Officer



MRI Interventions, Inc. Announces Record 629 ClearPoint® Cases in 2017

2017 Functional Neurology Product Revenue Increases 34%, Total Revenue Increases 28% Over 2016

IRVINE, CA, February 6, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on precision MRI-Guided Neurosurgical procedures, today announced revenues for the fourth quarter and full year ended December 31, 2017.

Joe Burnett, President & CEO of MRI Interventions, said, “We generated another year of strong growth with cases increasing 25% for the full year and 26% for the fourth quarter. We believe this is the primary measure of growing market interest in ClearPoint and our increasing competitiveness in this space. We also made significant progress in scaling the business along our planned path to profitability, reporting a 28% increase in total revenue, to \$7.4 million for the full-year 2017.

“Additionally, we believe MRI is well positioned for further growth in its biologic and drug delivery platform. As previously announced, Voyager Therapeutics (“Voyager”) recently gained FDA clearance to begin Phase II and Phase III studies, which we expect will result in additional product orders in 2018.

“We also have a strong pipeline of more than 40 candidate centers for new ClearPoint installations at various stages of the system evaluation and purchase process. We look forward to adding a number of these centers in 2018 to our current installed base of 52 active ClearPoint users.”

Year Ended December 31, 2017

The ClearPoint Neuro Navigation System was utilized in a record 629 cases, an increase of 25% from 504 cases in 2016. Total revenue increased 28%, to \$7.4 million, from \$5.7 million in 2016.

Functional neurology revenue, which consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased 34%, to \$5.3 million from \$4.0 million in 2016, reflecting continued growing adoption of the ClearPoint system.

Biologics and drug delivery systems revenue, which consists primarily of disposable product sales related to customer-sponsored clinical trials utilizing the ClearPoint system, were \$563,000, as compared with \$771,000 in 2016. This fluctuation arose from \$222,000 in advance purchases of such products by Voyager in late 2016, which have been subsequently used in Voyager’s clinical trials.

Capital equipment revenue, consisting of sales, rentals and service of ClearPoint reusable hardware and software, increased 50%, to \$1.5 million, from \$980,000 in 2016.

Quarter Ended December 31, 2017

The ClearPoint Neuro Navigation system was utilized in 161 cases in the fourth quarter of 2017, an increase of 26% from 128 cases in the 2016 fourth quarter. Total revenue was \$1.7 million, compared with \$1.6 million in the 2016 fourth quarter, an increase of 3%. The change in total revenue was

primarily attributable to the increase in functional neurology revenue, offset by the previously mentioned \$222,000 advance purchases of drug delivery products in 2016.

Functional neurology revenue increased 23%, to \$1.3 million from \$1.0 million in the fourth quarter of 2016, resulting from the increase in number of cases using the ClearPoint system.

Drug delivery product revenue for the fourth quarter of 2017 was \$120,000, a decline of 63% as compared with \$327,000 during the same period in 2016, reflecting the advance purchase in 2016 of drug delivery cannulas and related products.

Capital equipment revenue was \$291,000 in the fourth quarter of 2017, as compared with \$272,000 during the same period in 2016.

MRI Interventions plans a full release of its results for the three months and year ended December 31, 2017 in March 2018.

About MRI Interventions, Inc.

Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the company’s ClearPoint Neuro Navigation System products; and the company’s ability to market, commercialize and achieve broader market acceptance for the company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the company’s actual results are described in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, both of which have been filed with the Securities and Exchange Commission.

For Investors:

Matt Kreps, Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com